Crush the tablet in a mortar, add 15 mL water, draw the suspension into the syringe and administer immediately

The tablet should be diluted with at least 75 mL of water (to be avoided in patients on a low sodium diet or with phenylketonuria) If symptoms persist, a clinical reassessment should be considered. Medicinal products containing vitamin B1 or its derivatives may, especially when administered parenterally, induce the onset of atopic manifestations in patients with hypersensitivity. Important information about some of the excipients BIOCHETASI effervescent granules contain sorbitol and fructose. Patients with hereditary fructose intolerance should not be given this medicinal product. The additive effect of co-administration of medicinal products containing sorbitol or fructose and the daily dietary intake of sorbitol or fructose should be considered. The sorbitol content in oral medicinal products may modify the bioavailability of other co-administered oral medicinal products. BIOCHETASI effervescent granules contain glucose. Patients with rare glucose-galactose malabsorption problems should not take this medicine. BIOCHETASI effervescent granules contain sucrose. Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicinal product. BIOCHETASI effervescent granules contain approximately 1.7 g of sucrose and 1.4 g of glucose per dose (sachet). This should be taken into account in diabetic patients and in patients on low-calorie diets. BIOCHETASI effervescent granules contain 142 mg of sodium per sachet equivalent to 7.1% of the WHO recommended maximum daily intake which corresponds to 2 g of sodium for an adult. The maximum daily dose of this product is equivalent to 42.6% of the WHO recommended maximum daily intake for sodium. BIOCHETASI effervescent granules are considered high in sodium. To be taken into consideration especially in people on a low sodium diet. BIOCHETASI effervescent tablets contain aspartame, a source of phenylalanine, which can be harmful for patients with phenylketonuria. There are no non-clinical or clinical studies on the use of aspartame in infants younger than 12 weeks of age. BIOCHETASI effervescent tablets contain sucrose. Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicinal product. BIOCHETASI effervescent tablets contain 238 mg of sodium per dose equivalent to 11.9% of the WHO recommended maximum daily intake which corresponds to 2 g of sodium for an adult. The maximum daily dose of this product is equivalent to 71.4% of the WHO recommended maximum daily intake for sodium. BIOCHETASI effervescent granules are considered high in sodium. To be taken into consideration especially in people on a low sodium diet. Pregnancy and breastfeeding Grind, disperse the tablet in 10 mL water and administer immediately. Where possible switch to intramuscular administration Grind the tablet, dissolve it in 10 mL water and administer immediately preferably concomitantly with EN to minimize gastrointestinal effectsGrind the tablet, dissolve the powder in 10 mL water by shaking for 5 min, then administer immediately Adults and children over 12 years of age: 2 sachets or 2 effervescent tablets 3 times a day, dissolved in half a glass of water. Children under 12 years of age: half dose. Special populations Patients with hepatic insufficiency: No studies have been conducted with Bioketase in patients with hepatic insufficiency. Patients with renal insufficiency: No studies have been conducted with Bioketase in patients with renal insufficiency. Contraindications The effervescent tablets are the first choice (to be avoided in patients on a low sodium diet or with phenylketonuria)

Tablet crushing reduces AUC by approximately 40% Preferred alternative: Kaletra oral solution (slightly viscous, contains alcohol and propylene glycol) The best choice of a formulation to be administered via tube could be represented by a liquid one. Indeed, the liquid formulations can be easily administered with sufficient tranquility by means of a tube and generally they are immediately diluted in gastric juices and promptly absorbed. However, the assumption that liquid formulations are the first choice may be questionable. Cosolvents, such as ethanol, glycerol, and propylene glycol, may be present in all drug formulations being used and the acceptable daily intake (ADI) may be easily exceeded. Therefore, before shifting from a solid dosage form to a liquid, it is recommended to consider this worrying issue, i.e., ranitidine syrup (Ranidil 150 mg/10 mL) [ 16]. Remember, you can always text, call, or whatsapp MedInAction for a FREE consultation for your medical needs. Try out our new iOS app too and chat for free with the doctor. Alternative: effervescent tablets to be dissolved in water and administered after the end of the effervescenceIdentifica in maniera anonima un device (ad es. laptop, tablet, smartphone) e previene frodi per garantire transazioni sicure Alternatives: suppositories, orosoluble tablets, suppositories, drops to be diluted with 50 mL water Disperse the tablet in water without breaking it, under stirring for 15 min until a fine dispersion is obtained, then administer immediately away from the EN Alternatives: suppositories or oral suspension (to be diluted with water and administered at least 15 min before the start of EN)